BICISATE - bicisate injection, powder, lyophilized, for solution
AnazaoHealth Corporation
Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.
----------
Dear Medical Professional,
Per your order, we have compounded ECD as a sterile freeze-dried preparation. The characteristics of this preparation are:
AnazaoHealth supplies ECD as a compounded kit for preparing Tc99m ECD. Each Reaction vial contains 1.35 mg of ECD, 0.54 edetate disodium, 36mg mannitol and 0.125 mg stannous chloride dehydrate. The vial is back filled with inert gas and may contain a partial vacuum.
Each ECD buffer vial contains a total volume of 1 mL that includes 6.15 mg sodium phosphate dibasic and 0.69 mg sodium phosphate monobasic
Tc99m Bicisate forms a stable, lipophilic complex that crosses intact cell membranes and blood brain barrier by passive diffusion. The amount of tc99m bicisate is stable in the brain until about 6 hours
Tc99m bicisate is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed
For best results, use tc99m from a generator eluted within 24 hours. The eluate should be used within 2 hours of elution.
Reconstitution Instructions:
It is recommended that the kit be stored refrigerated until use; at such time the product should be aseptically withdrawn
BICISATE
bicisate injection, powder, lyophilized, for solution |
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
|||||||||||||||
|
Labeler - AnazaoHealth Corporation (011038762) |
Establishment | |||
Name | Address | ID/FEI | Business Operations |
---|---|---|---|
AnazaoHealth Corporation | 011038762 | MANUFACTURE(51808-217) |